Callan Family Office LLC Boosts Stock Holdings in Sanofi $SNY

Callan Family Office LLC grew its position in shares of Sanofi (NASDAQ:SNY) by 228.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 235,522 shares of the company’s stock after buying an additional 163,920 shares during the quarter. Callan Family Office LLC’s holdings in Sanofi were worth $11,378,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its position in Sanofi by 1.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company’s stock worth $612,106,000 after acquiring an additional 193,196 shares during the period. Federated Hermes Inc. raised its position in shares of Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after purchasing an additional 1,456,269 shares during the period. Envestnet Asset Management Inc. increased its holdings in Sanofi by 6.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company’s stock valued at $181,764,000 after acquiring an additional 211,641 shares during the last quarter. Raymond James Financial Inc. increased its holdings in Sanofi by 15.1% in the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after acquiring an additional 425,597 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Sanofi in the 1st quarter valued at $177,831,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $48.82 on Friday. The firm has a 50-day simple moving average of $48.25 and a 200-day simple moving average of $49.87. The stock has a market capitalization of $119.88 billion, a price-to-earnings ratio of 11.74, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the company earned $1.73 earnings per share. On average, equities analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SNY. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Finally, Barclays reiterated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.